Table 1.

Summary of MCL-AHN cases.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age (at diagnosis of first hematologic malignancy), race, and gender	45 yo Caucasian male	71 yo Caucasian male	74 yo Caucasian male	60 yo Caucasian male	68 yo Caucasian female
MCL type	Aleukemic de novo MCL	Aleukemic de novo MCL, subsequent diagnosis	Aleukemic secondary MCL, subsequent diagnosis	Aleukemic secondary MCL, subsequent diagnosis	Aleukemic de novo MCL, subsequent diagnosis
AHN type	AML without maturation	ETP-ALL	MDS with ringed sideroblasts	AML NOS	AML with t(8;21)
Aspirate findings at diagnosis	23% blasts and 48% mast cells	31% lymphoblasts on initial aspirate, 63% mast cells on aspirate	3% myeloblasts on initial aspirate, 20% mast cells on subsequent aspirate	78% myeloblasts and <5% mast cells on initial aspirate, 37% mast cells on subsequent aspirate	72% myeloblasts on initial aspirate, 34% mast cells on subsequent aspirate
Cytogenetics	Trisomy 8q, trisomy 21	Normal 46, XY male karyotype	Normal 46, XY male karyotype	Failed cytogenetics	Positive RUNX1T1/RUNX1 fusion
S/A/R status‡	S/A/Rpos	Unknown	S/A/Rneg	Unknown	S/A/Rneg
Outcome	Alive	Deceased	Deceased	Deceased	Deceased
Interval time between MCL and AHN	Concurrent diagnoses	3 months	9 years 10 months	10 months	2 months
Survival time from first diagnosed malignancy	17 months	21 months	14 years 3 months	21 months	47 months

MCL, mast cell leukemia; AHN, associated hematologic neoplasm; AML, acute myeloid leukemia; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; ^‡ S/A/R status indicates any mutation present in panel of SRSF2, ASXL1, and RUNX1.